Social Cost and Market

The pervasiveness of psychiatric disorders, e.g., depression, substance abuse, anxiety, schizophrenia, etc., and the comorbidity of depression and anxiety with neurological disease has enormous costs for society, estimated in the trillions of dollars. Additionally, it has been estimated that over 60% of individuals with diagnosable mental disorders do not seek treatment.

Various projections indicate that sales of drugs to treat neurological diseases alone will approach $20 billion by 2007 reflecting an absence of effective treatments for AD and the use of generic L-dopa as first-line treatment for Parkinson's disease. Drugs for the treatment of psychiatric disorders represent a much larger market with sales of the selective 5HT reuptake inhibitor (SSRI) class of antidepressants currently in the $10 billion range. Together the current market for CNS drugs is in excess of $70 billion. Should effective drugs be identified for the treatment of AD, this will account for an additional $6-8 billion in sales given the incidence of these diseases and their long-term nature. At the decade beginning in 2001, the global CNS drug market (including pain) was approximately $50 billion1 with estimates of $105 billion in 2005, $200 billion in 2010, and one estimate2 approaching $1.2 trillion.

Do Not Panic

Do Not Panic

This guide Don't Panic has tips and additional information on what you should do when you are experiencing an anxiety or panic attack. With so much going on in the world today with taking care of your family, working full time, dealing with office politics and other things, you could experience a serious meltdown. All of these things could at one point cause you to stress out and snap.

Get My Free Ebook


Post a comment